Discussion

With an increasingly elderly population, the prevalence of Alzheimer’s disease (AD) is set to increase dramatically. Given the cost and complexity of caring for patients with dementia, there is an urgent need for medicines or other interventions that delay, or deflect the course of the disease. Despite many attempts, no disease-modifying drug has yet met its primary outcome measures for AD. There is much to be learned by reviewing what we know about the temporal course of Alzheimer’s disease, the interplay of the major pathologies, and the preclinical to clinical translation of potential AD therapeutics.